Poor
Not Aligned
Patient Risk:
Low
Summary
Only one claim is partially supported by the provided label text; the remaining claims are absent from the label. Several statements (pricing, patent/monopoly, comparative potency, and generic-market assertions) are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Lipitor is used to lower cholesterol levels in patients with high cholesterol or heart disease.
Supported in part by 1 INDICATIONS AND USAGE sections provided: (a) prevention of cardiovascular disease/risk reduction in patients with clinically evident coronary heart disease and/or multiple risk factors; (b) hyperlipidemia indications as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG.
Unsupported Statements
The average retail price of Lipitor in the United States is around $140 per month for a 30-day supply of 10 mg tablets.
Absent from the provided FDA label text.
The average retail price of Pravastatin in the United States is around $20 per month for a 30-day supply of 10 mg tablets.
Absent from the provided FDA label text.
Lipitor was first approved by the FDA in 1997.
Absent from the provided FDA label text.
Lipitor was protected by patent until 2011.
Absent from the provided FDA label text.
While protected by patent, Pfizer had a monopoly on the market for Lipitor and could charge high prices.
Absent from the provided FDA label text.
Pravastatin is a generic medication that is no longer protected by patent.
Absent from the provided FDA label text.
Pravastatin can be manufactured by multiple companies.
Absent from the provided FDA label text.
The high cost of Lipitor is largely due to patent protection, marketing and advertising, research and development, and distribution and retail.
Absent from the provided FDA label text.
Generic medications are often cheaper because they do not require the same level of research and development as brand-name medications.
Absent from the provided FDA label text.
Generic medications are often manufactured by multiple companies, which can drive down prices.
Absent from the provided FDA label text.
Generic medications like Pravastatin can provide cost savings.
Absent from the provided FDA label text.
Generic medications like Pravastatin can provide increased access.
Absent from the provided FDA label text.
The introduction of generic medications like Pravastatin can drive down prices and increase competition in the market.
Absent from the provided FDA label text.
Lipitor is a potent statin.
Absent from the provided FDA label text (no potency characterization provided in the provided sections).
Pravastatin is a less potent statin.
Absent from the provided FDA label text (comparative potency statement not supported by supplied label content).
Pravastatin is often prescribed for patients with mild to moderate high cholesterol.
Absent from the provided FDA label text (no such prescribing-frequency or severity description provided).
Contradictions
Important Omissions
Full prescribing-information content needed to evaluate contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, storage/handling, and specific-population dosing/safety (pregnancy, lactation, pediatrics, renal/hepatic impairment). The provided label excerpts include only Indications/Usage and a portion of Dosage/Administration plus some Clinical Pharmacology text.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily economic/competitive and general product-characterization statements, with only one partially label-supported indication claim. However, key safety-critical label sections were not provided, preventing evaluation of medication safety accuracy for dosing/contraindications/warnings/interactions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are absent from the provided FDA label text, including pricing, approval/patent/monopoly assertions, generic market behavior, and comparative potency statements.
Suggested Improvement
Limit claims strictly to the provided (or fully supplied) FDA-approved label sections; remove or reframe all statements not present in the prescribing information, and provide full label sections (including contraindications, boxed warnings, warnings/precautions, interactions, adverse reactions, and specific-population information) for comprehensive audit.